bluuebunny/crossref_metadata_2025_split huggingface dataset:
CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
Authors: Ekhator Chukwuyem , Kesari Santosh , Tadipatri Ramya , Fonkem Ekokobe , Grewal Jai 
Published: August 2022

Abstract

OBJECTIVE
To report a summary of a systematic review of virtual tumor boards and their implementation in neuro- oncology.

BACKGROUND
Virtual tumor board [VTB] platforms are an important aspect of cancer management. They enable easier access to a multidisciplinary team of experts. VTBs are an emerging resource across various cancer care networks in the United States.

DESIGN/METHODS
We performed a systematic search of all VTBs incorporating a platform designed for this specific role. We reviewed UC Davis Health Care Center VTB, Genomet, Oncolens, Navify Tumor Board, Medical University of South Carolina Virtual Tumor Board, Precision Oncology, Cancer Commons, Virtual Tumor Board, Virtual Tumor Board Tahoe Forest Cancer Center and MassiveBio. Summary data examined include year of launch, demographics, characteristics of cases, average response time, advantages, and how they handle protected health information.

RESULTS
30% of all VTBs examined launched in 2017. All had a HIPAA compliant online environment. Genomet VirtualBoard de-identifies all patient information; this is a virtual platform primarily focused on neuro-oncology cases. Cases involved a median of 5 specialists most commonly neuro-oncologists, neurosurgeons, radiation oncologists, molecular pathologists and neuroradiologists. Participants had an average of 23 cases reviewed. Case review revealed an age range from 6 months to 84 years [mean age 44.5 years] with 69.6% males and 30.4% females, 43.5% glioblastoma, 8.7% adenocarcinoma, 8.7% infratentorial tumor, &lt;5% each: pineoblastoma, melanoma, hemangioblastoma and pilocytic astrocytoma. Average response time observed in all cases was ≤24 hours. Detailed metrics for numbers/percentages of brain tumor cases were not available for most other platforms at time of submission. This will be updated at presentation.

CONCLUSIONS
VTBs have allowed for quicker expert analysis of cases. This has resulted in an accelerated number of cases reviewed with a shortened communication time. More studies are needed to gain additional insight into user engagement metrics.
SPIN-02 LEVERAGING AN MRI-GUIDED LINEAR ACCELERATOR PLATFORM FOR POST-OPERATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) OF SPINAL METASTASES
Authors: Marciscano Ariel E , Knisely Jonathan P S , Nagar Himanshu , Brandmaier Andrew , Pennell Ryan T , Speiser Michael , Kim Sungheon G , Coonce Madeline , Chen Shu Ling , Roytman Michelle , Lin Eaton , Ballman Karla V , Pannullo Susan C , Ramakrishna Rohan 
Published: August 2022

Abstract

PURPOSE/OBJECTIVE(S)
Post-operative spine SBRT presents unique clinical challenges. Spinal hardware produces CT and high-field strength MRI artifacts that obscure visualization of the spinal cord and unresected disease. Existing workflows incorporate additional invasive procedures with CT myelogram and quality control for these procedures can introduce uncertainty into SBRT planning. Reducing metallic imaging artifact with a low-field strength (0.35 T) MRI integrated into a MR-Linac (MRL) may facilitate superior visualization of the spinal cord, improved target delineation and treatment localization. The primary objective is to determine the feasibility of MRL-based simulation workflow to facilitate MR-guided post-operative spine SBRT without the need for CT myelogram or CT-based target delineation.

MATERIALS/METHODS
A single-institution, single-arm interventional feasibility study is planned. A total of 10 patients who underwent surgical resection of solid tumor spinal metastases with an indication for post-operative SBRT will be enrolled and undergo radiation planning and treatment on a MRL platform that combines a 6MV Linac and 0.35 T on-board MRI system. Enrolled subjects will undergo CT and MR simulation followed by standard-of-care post-operative spine SBRT and follow-up spine imaging every 3 months.

RESULTS
The primary endpoint is feasibility of MR-guided post-operative spine SBRT without CT myelogram. Feasibility is defined as &gt; 70% of participants with clinically acceptable visualization/delineation as determined by blinded dual neuroradiologist review for clinically acceptable visualization/delineation of organs-at-risk (OARs) and target volume(s). Exploratory endpoints involve radiation dosimetry analysis of OARs and target volumes as well as documenting the use of adaptive planning. Radiation site progression-free survival will be recorded at 6-months after SBRT.

CONCLUSION
If feasible, an MRL-based workflow for post-operative spine SBRT represents a patient-centric approach to improve efficiency, minimize treatment delays, and avoid invasive procedures that may improve clinical management of solid tumor spinal metastases.
LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL
Authors: Brenner Andrew , Youssef Michael , LaFrance Norman , Hedrick Marc , Bao Ande , Phillips William , Patel Torel , Weinberg Jeffrey , Floyd John 
Published: August 2022

Abstract

BACKGROUND
LM is a devastating subarachnoid (SA) complication most commonly from breast, lung, melanoma, and gastrointestinal malignancies affecting 110,000 in the USA. Common therapies are radiation and SA/IV chemotherapy. Without treatment, survival is short with limited treatment options and better options urgently needed. 186RNL emits beta particles (with gamma-rays) with low dose rate and high radiation density. We report first results of the enrolling ReSPECT-LM phase 1/2a 186RNL-LM dose escalation trial.

MATERIAL AND METHODS
Preclinical syngeneic rat model animals were 186RNLtreated at day15 with intraventricular186RNL(0.689 mCi) providing mean CSF-radiation absorbed dose=1,136 ±226Gy. 50% control animals[unloaded liposomes] and 100%186RNL treated animals were alive at 14days. At 4 weeks, 75% control animals and 37.5% treated animals had died. Based on this preclinical data and 186RNL recurrent glioma human experience, a phase I/2a dose escalation ReSPECT-LM Trial was initiated to characterize safety/tolerability of a single intrathecal(IT) 186RNL administration. Following, to identify maximum tolerated/feasible doses, 186RNL anti-tumor activity as a single agent in LM patients (breast and NSCLC), characterize 186RNL pK & dosimetry via Ommaya delivery, determine the overall response rate (ORR) for 186RNL treated patients based on CSF/radiographic findings, and describe survival distribution.

RESULTS
ReSPECT-LM is enrolling and 1st patient dosed (6.6 mCi186RNL, 5ml) via Ommaya reservoir. The dose was well-tolerated with no complaints/AEs as of Day 28 following treatment. Imaging and CSF tumor cell assays at pre &post-dose were performed. 186RNL gamma imaging confirmed rapid, complete and durable SA dose distribution through168hours. Pre-dose CSF tumor cell count was 70.77 cells/ml and following treatment, 39.79 cells/ml at 24, and ~6 cells/ml at both 48 &168hours.

CONCLUSION
186RNL’s unique formulation and characteristics may have promise for LM patients. An update of the ReSPECT-LM clinical trial will be provided.
MMAP-10 ADVERSE RADIATION EFFECT AFTER STEREOTACTIC RADIOSURGERY AND IMMUNOTHERAPY/TARGETED THERAPY FOR MELANOMA BRAIN METASTASES
Authors: Phuong Christina , Vasudevan Harish N , Chen William C , Raleigh David R , Fogh Shannon , Boreta Lauren , Daras Mariza , Tsai Katy , Nakamura Jean , Sneed Penny K , Braunstein Steve E 
Published: August 2022

Abstract

BACKGROUND
Safety of immunotherapy (IO) and targeted therapy (TT) with stereotactic radiosurgery (SRS) in melanoma brain metastases (MBM) treatment remains incompletely understood. We aim to identify whether timing of IO/TT in relation to SRS impacts rates of adverse radiation effect (ARE) in MBM.

METHODS
Retrospective review of patients with MBM treated with SRS and IO/TT within three months prior and one year after SRS, from 2011-2021 at a single institution with at least two months MRI follow-up, identified 108 patients with 939 unique MBM meeting criteria. ARE was confirmed on independent imaging review. Concurrent IO/TT was defined as receiving IO/TT within 4 weeks before or after SRS. Data analysis was performed with the univariate cox proportional hazard model and Kaplan-Meier method.

RESULTS
Median radiographic follow-up from time of SRS was 16months. IO/TT was initiated prior to SRS for 681 (72.5%) metastases and after SRS for 258 (27.5%) metastases. 837 (89.1%) metastases received concurrent IO/TT. Most common IO agents were ipilimumab (n=416), nivolumab (n=448), and pembrolizumab (n=203). Most common TT agents were dabrafenib (n=548), trametinib (n=540), and vemurafenib (n=81). 2-year local progression-free survival (PFS), distant intracranial PFS, and overall survival were 94.1%, 33.3%, and 55.2%, respectively. 55 (5.9%) metastases in 33 (30.6%) patients experienced ARE. Median time to ARE was 5mo (IQR 4-9mo). Of those who experienced ARE, 22 (66.7%) patients were symptomatic and treated with steroids; 12 (36.4%) patients underwent surgical intervention. ARE rates were not impacted by concurrent vs nonconcurrent IO/TT (5.5% vs 4.9%, p=0.34) nor IO/TT initiation pre vs post SRS (6.0% vs 5.4%, p=0.61).

CONCLUSION
IO/TT in conjunction with SRS resulted in low ARE rates as compared to historical controls in the pre-IO/TT era. Timing of IO/TT in relation to SRS may not significantly impact ARE rates in MBM treatment.
NEIM-05 FEASIBILITY OF NAVIGATED TRANSCRANIAL MAGNETIC STIMULATION (NTMS) BASED DIFFUSION TENSOR IMAGING (DTI) TRACTOGRAPHY OF MOTOR PATHWAYS IN PATIENTS UNDERGOING STEREOTACTIC RADIOSURGERY: A CROSS-SECTIONAL DOSIMETRIC AND PATIENT OUTCOMES ANALYSIS
Authors: Bronk Julianna , Muir Matthew , Michener Hayley , Calbat Courtney , Mackin Dennis , Mitchell Drew , Train Benjamin , Farhat Maguy , Elliot Andrew , Prabhu Sujit , Prinsloo Sarah , Chung Caroline 
Published: August 2022

Abstract

BACKGROUND
No current dose limitations exist for the motor tracts during stereotactic radiosurgery (SRS) planning due to challenges in localizing this region of interest by conventional imaging. Navigated Transcranial Magnetic Stimulation (nTMS) is a non-invasive tool that utilizes electromyographic signal combined with magnetic resonance diffusion tensor imaging (DTI) to functionally map cortical motor tracts. Although nTMS is utilized for functional mapping prior to brain tumor resection, it has not been implemented in SRS planning.

OBJECTIVES
To determine the feasibility of performing nTMS-based DTI in patients treated with SRS and examine the relationship between dose to functionally-defined motor tracts and patient outcomes measured by objective hand function testing and patient reported outcomes (PROs).

METHODS
16 patients treated with SRS to a brain metastasis located near anatomically-defined motor tracts were enrolled on an IRB-approved clinical trial. At median follow-up of 5.4m after SRS, patients underwent nTMS testing, brain MRI with DTI, functional outcomes testing (Pinch Dynamometer,9-Hole Peg Test), and quality-of-life (QOL) PROs (EQ-5D-5L, MDASI-BT). nTMS-seeded DTI tractography was generated (Brainlab iPlan) and imported into GammaPlan for dosimetric evaluation.

RESULTS
Tractography reconstitution was attempted for 8/16 patients and successful in 7/8 (87.5%). One patient who had prior resection of a lesion in the right pre-central gyrus failed to map in the right cortex and was unable to complete functional testing for the affected extremity. Median Dmax to the treated motor tracts was 4.6Gy [0.5-13.4Gy]. Median Dmean was 0.9Gy [0-1.2Gy]. Increased Dmax correlated with deficits in lateral pinch strength (R2=0.76) and 9-Hole Peg testing time (R2=0.61). Increased Dmean correlated with increased MDASI-BT interference scores (R2=0.93) and EQ5D5L score (R2=0.94) indicating worsened QOL.

CONCLUSIONS
nTMS testing was feasible and dose to nTMS-defined motor tracts correlated with subjective and objective patient outcomes. Future steps will include characterization of motor tract dose tolerance for SRS.
NEIM-08 A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH DOSE ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Kim Michelle , Aryal Madhava , Rosen Benjamin , Parmar Hemant , You Daekeun , Junck Larry , Leung Denise , Umemura Yoshie , Heth Jason , Al-Holou Wajd , Hollon Todd , Wahl Daniel , Lawrence Theodore , Cao Yue 
Published: August 2022

Abstract

BACKGROUND
Biologically-informed radiotherapy (RT) targeting an adversely prognostic hypercellular/hyperperfused imaging phenotype in patients with newly diagnosed glioblastoma (GBM) may improve outcomes by identifying emerging regions of treatment resistance associated with survival (OS), and is under investigation as a target for individualized, adaptive RT in an ongoing Phase II trial (NCT04574856).

METHODS
In this single-arm study, patients with newly diagnosed GBM following resection undergo dose-intensified chemoRT targeting the residual hypercellular (TVHCV, mean contralateral normal brain+2SD) and hyperperfused tumor volume (TVCBV, contralateral normal frontal grey matter+1SD) identified using high b-value diffusion-weighted and dynamic contrast-enhanced perfusion MRI. TVHCV/TVCBV is treated to 50 Gy in 20 fractions (2.5 Gy/fraction), and following mid-RT reassessment, the persistent and developing TVHCV/TVCBV is treated to 30 Gy in 10 fractions (3 Gy/fraction). The primary endpoint is improvement in OS, with planned interim safety analysis.

RESULTS
Since October 2020, 16 of 30 patients have been enrolled. Median age was 58 years (range, 29-75) and 69% were male. No patient underwent biopsy, and 50% had gross total resection; 23% had MGMT methylated tumors, and all except 2 were IDHwt. Median TVHCV/TVCBV was 6.9 cc (range, 1.9-42.8) pre-RT and 30% (range, 1-72%) was nonenhancing. By mid-RT, TVHCV/TVCBV was reduced to 4.2 cc (range, 0.8-34.3) and 47% (range, 3-74%) was nonenhancing. The TVHCV/TVCBV persisting from pre- to mid-RT was 2.3 cc (range, 0-24.2), with an additional 1.8 cc (range, 0.3-20.6) newly developing outside of the initial region. All patients underwent adaptive replanning for boost without interruption. Planned interim analysis determined an acceptable rate of neurologic toxicity and safety to continue enrollment.

CONCLUSION
Individualized, adaptive radiotherapy using an advanced imaging biomarker to assess emerging and especially non-enhancing regions of treatment resistance in patients with GBM is feasible, with short term safety in an early cohort and longer-term efficacy outcomes anticipated with ongoing accrual.
Non-daily Cigarette Smoking: Stability and Transition to Abstinence in Young Adults
Authors: Doran Neal , Myers Mark , Luczak Susan , Trim Ryan , Strong David , Tully Lyric 
Published: August 2022

Abstract

Introduction
There is increasing recognition that non-daily cigarette smoking is common in early adulthood but less is known about its stability over time, or what influences transitions to heavier or nonsmoking. We examined the stability of non-daily smoking in a sample of young adults, and tested whether social and cognitive factors predicted transitions to other smoking patterns over time.

Aims and Methods
Participants were 579 young adults (18–24 years old at enrollment, 52% male) who were non-daily and never-daily cigarette smokers and California residents. Participants completed 13 waves of assessment over 3 years. We used descriptive statistics to evaluate the frequency of consistent abstinence, defined as no cigarette use at two consecutive waves and no cigarette use at any subsequent waves. Cox and logistic regression were used to test predictors of consistent abstinence.

Results
We found that 55% of participants smoked intermittently throughout the study, while 43% were consistently abstinent by the end of the study; few transitioned to daily smoking. Stopping smoking was associated with having fewer smoking friends, smoking less in social situations, having lower positive reinforcement expectancies for smoking, and having stronger intent to quit. Post hoc analyses indicated those who stopped smoking tended to report reductions in positive reinforcement expectancies and increased intent to quit in the 6 months before stopping.

Conclusions
Findings suggest a substantial minority of young adult non-daily smokers may stop on their own, but that the majority continue smoking and may require intervention. Interventions for this population should address social motives and reinforcement expectancies.

Implications
The majority of young adults who are non-daily cigarette smokers appear to maintain this habit over an extended period and may require intervention. Interventions that focus on reducing expectancies for positive effects of and social motives for cigarette use and on increasing intent to quit smoking may be most effective.
Patient Engagement by the Tobacco Quitline After Electronic Referrals
Authors: Khanna Niharika , Klyushnenkova Elena N , Quinn David , Wolfe Sara 
Published: August 2022

AbstractIntroductionReferrals through the electronic health record (EHR) system provide an efficient evidence-based method to connect patients to the Tobacco Quitline. However, patients frequently do not respond to Quitline phone calls or accept services. The goal of this study was to characterize factors associated with successful engagement with Quitline following e-referrals by physicians in Maryland.Aims and MethodsThis is a cross-sectional study with hierarchical data modeling. Data for 1790 patients e-referred in 2018–2019 by the University of Maryland Medical System (UMMS) were analyzed. Patients’ engagement was assessed using a generalized estimating equation multivariable regression model for ordinal outcomes at two levels: Picking up a phone call from Quitline (1-800-QUIT-NOW) and enrollment in tobacco cessation programs.ResultsOlder age, female gender, black race, low socioeconomic status, and provider’s skills were significantly associated with successful outcomes of Quitline referral. The engagement with Quitline was higher in black non-Hispanic patients compared to other racial/ethnic groups (phone call response odds ratio [OR] = 1.99, 95% confidence interval [CI] = 1.35% to 2.93% and service acceptance OR = 1.89, 95% CI = 1.28% to 2.79%). Patients residing in socioeconomically deprived areas were more likely to respond to Quitline phone calls compared to those from affluent neighborhoods (OR = 1.52, 95% CI = 1.03% to 2.25%). Patients referred by faculty or attending physicians were more likely to respond compared to those referred by residents (OR = 1.23, 95% CI 1.04, 1.44, p = .0141).ConclusionsMultiple factors impact successful engagement with Quitline. Additional means to improve Quitline engagement success may include focused messaging on tobacco cessation benefits to patients, and skillful counseling by the provider.ImplicationsImplementation of the clinical decision support (CDS) tool for electronic referrals to the Tobacco Quitline at the UMMS was successful in providing evidence-based free service to elderly patients and socioeconomically disadvantaged racial and ethnic minorities. The CDS also served to engage physicians in conversation about tobacco use and cessation with every tobacco-using patient. Curricular content for physicians in training should be enriched to expand tobacco use and treatment.
Wavelets and sparsity for Faraday tomography
Authors: Cooray Suchetha , Takeuchi Tsutomu T , Ideguchi Shinsuke , Akahori Takuya , Miyashita Yoshimitsu , Takahashi Keitaro 
Published: August 2022

AbstractFaraday tomography through broad-band polarimetry can provide crucial information on magnetized astronomical objects, such as quasars, galaxies, or galaxy clusters. However, the limited wavelength coverage of the instruments requires that we solve an ill-posed inverse problem when we want to obtain the Faraday dispersion function (FDF), a tomographic distribution of the magneto-ionic media along the line of sight. This paper explores the use of wavelet transforms and the sparsity of the transformed FDFs in the form of wavelet shrinkage (WS) for finding better solutions to the inverse problem. We recently proposed the Constraining and Restoring iterative Algorithm for Faraday Tomography (CRAFT; Cooray et al. 2021, MNRAS, 500, 5129), a new flexible algorithm that showed significant improvements over the popular methods such as Rotation Measure Synthesis. In this work, we introduce CRAFT + WS, a new version of CRAFT incorporating the ideas of wavelets and sparsity. CRAFT + WS exhibits significant improvements over the original CRAFT when tested for a complex FDF of a realistic Galactic model. Reconstructions of FDFs demonstrate super-resolution in Faraday depth, uncovering previously unseen Faraday complexities in observations. The proposed approach will be necessary for effective cosmic magnetism studies using the Square Kilometre Array and its precursors. The code is made publicly available at 〈https://github.com/suchethac/craft〉.
Transcriptional network underpinning ploidy-related elevated leaf potassium in neo-tetraploids
Authors: Fischer Sina , Flis Paulina , Zhao Fang-Jie , Salt David E 
Published: August 2022

Abstract
Whole-genome duplication generates a tetraploid from a diploid. Newly created tetraploids (neo-tetraploids) of Arabidopsis (Arabidopsis thaliana) have elevated leaf potassium (K), compared to their diploid progenitor. Micro-grafting has previously established that this elevated leaf K is driven by processes within the root. Here, mutational analysis revealed that the K+-uptake transporters K+ TRANSPORTER 1 (AKT1) and HIGH AFFINITY K+ TRANSPORTER 5 (HAK5) are not necessary for the difference in leaf K caused by whole-genome duplication. However, the endodermis and salt overly sensitive and abscisic acid-related signaling were necessary for the elevated leaf K in neo-tetraploids. Contrasting the root transcriptomes of neo-tetraploid and diploid wild-type and mutants that suppress the neo-tetraploid elevated leaf K phenotype allowed us to identify a core set of 92 differentially expressed genes associated with the difference in leaf K between neo-tetraploids and their diploid progenitor. This core set of genes connected whole-genome duplication with the difference in leaf K between neo-tetraploids and their diploid progenitors. The set of genes is enriched in functions such as cell wall and Casparian strip development and ion transport in the endodermis, root hairs, and procambium. This gene set provides tools to test the intriguing idea of recreating the physiological effects of whole-genome duplication within a diploid genome.